Arun Menawat, Chairman & CEO, emphasized the completion of recruitment for CAPTAIN, the first multicenter, randomized, controlled trial comparing a new technology to robotic radical prostatectomy, ...

Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...